Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Indivior PLC - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
INDV
Nasdaq
2830
www.indivior.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Indivior PLC
Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV)
- Jan 31st, 2025 1:33 pm
Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year
- Jan 21st, 2025 5:02 am
Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years
- Dec 11th, 2024 6:48 am
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...
- Nov 23rd, 2024 7:01 am
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
- Nov 19th, 2024 5:52 pm
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
- Nov 7th, 2024 7:24 pm
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
- Oct 30th, 2024 4:30 pm
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...
- Oct 25th, 2024 7:07 am
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates
- Oct 24th, 2024 11:05 am
Indivior Announces Q3 2024 Financial Results
- Oct 24th, 2024 6:00 am
Two Seas Capital LP Increases Stake in Indivior PLC
- Oct 17th, 2024 9:03 pm
Indivior price target lowered to $16 from $20 at Craig-Hallum
- Oct 12th, 2024 12:35 pm
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...
- Oct 11th, 2024 7:00 am
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
- Oct 10th, 2024 1:28 pm
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook
- Oct 10th, 2024 1:08 pm
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
- Oct 10th, 2024 11:00 am
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
- Oct 7th, 2024 3:30 pm
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...
- Oct 1st, 2024 7:00 am
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
- Sep 25th, 2024 8:34 am
Top 3 Health Care Stocks That May Explode This Month
- Sep 23rd, 2024 6:00 pm
Scroll